Adverse events regardless of relationship to imatinib
| AEs in 30% or more of patients . | % AEs all grades, n = 532 . | % SAEs before July 31, 2002, n = 532 . | % SAEs* after July 31, 2002, n = 395 . |
|---|---|---|---|
| Fluid retention | 69 | 2 | 3 |
| Superficial edema | 67 | <1 | 1 |
| Other fluid retention | 7 | 1 | 1 |
| Nausea | 63 | 1 | 3 |
| Muscle cramps | 62 | — | <1 |
| Diarrhea | 48 | 1 | 3 |
| Fatigue | 48 | — | <1 |
| Rash and related terms | 47 | 1 | <1 |
| Arthralgia | 40 | <1 | <1 |
| Musculoskeletal pain | 38 | <1 | 2 |
| Vomiting | 36 | 1 | 3 |
| Headache | 36 | — | <1 |
| Abdominal pain | 32 | 1 | 2 |
| Weight increased | 32 | — | — |
| Hemorrhages | 30 | 3 | 5 |
| AEs in 30% or more of patients . | % AEs all grades, n = 532 . | % SAEs before July 31, 2002, n = 532 . | % SAEs* after July 31, 2002, n = 395 . |
|---|---|---|---|
| Fluid retention | 69 | 2 | 3 |
| Superficial edema | 67 | <1 | 1 |
| Other fluid retention | 7 | 1 | 1 |
| Nausea | 63 | 1 | 3 |
| Muscle cramps | 62 | — | <1 |
| Diarrhea | 48 | 1 | 3 |
| Fatigue | 48 | — | <1 |
| Rash and related terms | 47 | 1 | <1 |
| Arthralgia | 40 | <1 | <1 |
| Musculoskeletal pain | 38 | <1 | 2 |
| Vomiting | 36 | 1 | 3 |
| Headache | 36 | — | <1 |
| Abdominal pain | 32 | 1 | 2 |
| Weight increased | 32 | — | — |
| Hemorrhages | 30 | 3 | 5 |
Based on 395 patients on study at the July 31, 2002, date.